Rule 3.8A

## **Appendix 3E**

## Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

*Information and documents given to ASX become ASX's property and may be made public.*Introduced 1/9/99. Origin: rule 3.6, Appendix 7C. Amended 30/9/2001.

Name	of entity	ABN	
BIOTECH CAPITAL LIMITED			45 091 979 172
We (	(the entity) give ASX the following	information.	
Info	ormation about buy-back		
1	Type of buy-back	On-Market	
2	Date Appendix 3C was given to ASX	24 November 2009	
	al of all shares bought back n received, before, and on, p	·	Previous day (close 21/5/10)
3	Number of shares bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	4,624,592	7,447
4	•		
4	Total consideration paid or payable for the shares	\$1,271,805.82	\$1,787.28

30/9/2001 Appendix 3E Page 1

<sup>+</sup> See chapter 19 for defined terms.

		Before previous day	Previous day (close 21/5/10)			
5	If buy-back is an on-market buy-back	highest price paid: \$0.24	highest price paid: \$0.24			
		lowest price paid: \$0.235	lowest price paid: \$0.24			
			highest price allowed under rule 7.33: \$0.252			
Participation by directors						
6	Deleted 30/9/2001.	Nil				
How many shares may still be bought back?						
7	If the company has disclosed an intention to buy back a maximum number of shares - the remaining number of shares to be bought back	3,348,438				
Compliance statement						
1.	The company is in compliant this buy-back.	ne company is in compliance with all Corporations Act requirements relevant to is buy-back.				
2.	There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.					
Sign		Baden Bowen Date: 21/5/10(Company Secretary)				
Print	name: Baden M Bowen	Baden M Bowen				

Appendix 3E Page 2 30/9/2001

== == == ==

<sup>+</sup> See chapter 19 for defined terms.